A Review of the Preclinical Development of Zaleplon, a Novel Non‐Benzodiazepine Hypnotic for the Treatment of Insomnia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
SUMMARY: Zaleplon (N‐[3‐(3‐cyanopyrazolo[l,5‐a]pyrimidin‐7‐y l)phenyl)]‐N‐ethylacetamide) is a non‐benzodiazepine sedative‐hypnotic with benzodiazepine‐like sedative effects, but with less apparent liability for accompanying undesirable side effects. Zaleplon displaces [3 H]flunitrazepam from rat cortical membranes with an IC 50 value of 200 nM and enhances t‐butylbicyclophosphorothionate [35 S]TBPS binding by 73%, suggesting pharmacological activity mediated by the GABA A benzodiazepine receptor complex. In various preclinical procedures such as motor activity, muscle relaxation, EEG, anticonvulsant activity, and vigilance, zaleplon produced effects similar to those of other sedative‐hypnotic compounds such as triazolam and flurazepam; furthermore, these effects, when evaluated, were reversed by the benzodiazepine receptor antagonist flumazenil. Zaleplon increased punished (conflict) responding in squirrel monkeys and rats and these effects were also antagonized by flumazenil. When established as a discriminative stimulus in rats at 3.0mg/kg i.p., zaleplon showed a dose‐related increase in drug‐appropriate responding up to the training dose and a correlated decrease in response rate. Triazolam (0.1 to 1.0 mg/kg), the benzodiazepine partial agonist Ro 17‐1812 (0.3 to 3.0mg/kg), and the triazolopyridine CL 218,872 (1.0 to 3.0 mg/kg) substituted consistently for zaleplon in all rats, whereas the imidazo‐pyridines zolpidem (3.0 to 10 mg/kg) and alpidem (10 to 30 mg/kg), the benzodiazepine partial agonist bretazenil (0.03 to 10 mg/kg) and the novel putative anxio‐lytic CL 273,547 (10 to 56 mg/kg) did not result in consistent drug‐appropriate responding in all rats. These results suggest that the effects of zaleplon are similar in many respects to other compounds acting at the benzodiazepine receptor complex but differ as well from both benzodiazepine and non‐ benzodiazepine drugs. This profile of activity, coupled with additional information in ancillary procedures, yields a pre‐clinical profile of a short‐acting sedative‐hypnotic non‐benzodiazepine that is currently in Phase III development for the treatment of sleep disturbances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., & Weerts, E. M. (1997) · Psychopharmacology · doi:10.1007/s002130050422 · Cited by 260
Cited by
Zaleplon: A Review of its Use in the Treatment of Insomnia
Dooley, M., & Plosker, G. L. (2000) · Drugs · doi:10.2165/00003495-200060020-00014 · Cited by 287
Medicinal attributes of pyrazolo[3,4-d]pyrimidines: A review
Chauhan, M., & Kumar, R. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.07.027 · Cited by 168
IS THERE A RATIONALE FOR PRESCRIPTION OF BENZODIAZEPINES IN THE ELDERLY? REVIEW OF THE LITERATURE
Petrovic, M., Mariman, A., Warie, H., Afschrift, M., & Pevernagie, D. (2003) · Acta Clinica Belgica · doi:10.1179/acb.2003.58.1.004 · Cited by 76
“Its primary clinical advantage over other medications for insomnia is its short elimination half-life of approximately one hour (74).”
BackgroundAtor, N. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900009883 · Cited by 59
The Pharmacology and Mechanism of Action of Zolpidem
Sanger, D. J., & Depoortere, H. (1998) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1998.tb00074.x · Cited by 58
“1 in comparison with two other non-benzodiazepines, zopiclone, which is also used in the treatment of insomnia (54) and zaleplon which is in clinical development also as a hypnotic (8).”
Metadata
- Authors
- Beer, B., Clody, D. E., Mangano, R., Levner, M., Mayer, P., & Barrett, J. E.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 1997-09
- Volume
- 3
- Issue
- 3
- Pages
- 207-224
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2012011634
- Cited by
- 40
- References
- 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of the Preclinical Development of Zaleplon, a Novel Non‐Benzodiazepine Hypnotic for the Treatment of Insomnia. https://app.cochat.ai/papers/10.1111/j.1527-3458.1997.tb00324.x
- The paper
- Beer, B., Clody, D. E., Mangano, R., Levner, M., Mayer, P., & Barrett, J. E. (1997). A Review of the Preclinical Development of Zaleplon, a Novel Non‐Benzodiazepine Hypnotic for the Treatment of Insomnia. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.1997.tb00324.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.